GLP1R and Alzheimer disease: Given that ageing-associated NVU dysfunction represents a common component for AD and other neurodegenerative conditions, our study shows that reversal of ageing-associated changes in brain ECs and BBB protection is an important underlying mechanism that explains GLP-1R agonists’ general applicability as potential disease-modifying therapeutics.